Searchable abstracts of presentations at key conferences in endocrinology

ea0038p220 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Endogenous ARX knockdown enhances beta-cell lineage specification and maturation during ex vivo transdifferentiation of human exocrine pancreatic tissue

Lima Maria Joao , Docherty Hilary M , Muir Kenneth R , Forbes Shareen , Casey John , Docherty Kevin

The shortage of donor material has driven research towards finding a replenishable supply of islets for transplantation. We have previously shown that the exocrine material that results as a by-product of the islet isolation procedure can be transdifferentiated towards functional islet-like structures by overexpression of the pancreatic transcription factors (TFs) Pdx1, MafA, Ngn3 and Pax4 followed by culture in the presence of betacellulin, nicotinamide and exendin-4. These c...

ea0013p163 | Diabetes, metabolism and cardiovascular | SFEBES2007

An engineered zinc finger transcription factor that activates the endogenous human insulin gene in non β cells

Ferguson Laura , Docherty Hilary , Docherty Kevin

The insulin gene is expressed almost exclusively in the β cells of the islets of Langerhans, where transcriptional control is conferred by cis-acting regulatory sequences located within 300–400 base pairs from the transcription start site. These elements bind β-cell restricted (e.g. PDX-1) and ubiquitous (E47) transcription factors. In non-β cells the insulin gene is localised within tightly packed (hetero) chromatin structures. Developments in under...

ea0015s7biog | Society for Endocrinology Medal Lecture | SFEBES2008

Society for Endocrinology Medal Lecture

Critchley Hilary

Hilary Critchley, University of Edinburgh, Edinburgh, UK AbstractHilary Critchley is Professor of Reproductive Medicine (Personal Chair awarded 1999) at the University of Edinburgh and clinical Consultant in Obstetrics and Gynaecology at the Royal Infirmary, Edinburgh.She graduated in medicine from the University of Manchester. Her research training was undertaken with Professor David Baird (Edin...

ea0029p1166 | Nuclear receptors and Signal transduction | ICEECE2012

Evaluation of K+ flux-dependent regulation of mitochondrial potential (ΔΨm) by α-adrenergic agonist phenylephrine in single hepatocytes

Malyukina M. , Kavok N.

It is generally accepted that hepatic responses to α-adrenergic agonists are dependent on the redistribution of intracellular and also extracellular Ca2+. Besides, phenylephrine induces significant K+ flux changes and plasma membrane hyperpolarisation. Earlier it was shown that K+ channel blockers as well as chelating of extracellular Ca2+ with EGTA could inhibit phenylephrine-induced metabolic responses and activation of mitoch...

ea0049ep598 | Diabetes therapy | ECE2017

The hypolipidemic and hepatoprotective efficacies of a fixed-dose combination of essential phospholipids with methionine (EPL+M) during atorvastatin (A) therapy in hyperlipidemic patients with cardiovascular diseases (CVD) and type 2 diabetes mellitus (DM) (OLYMP trial)

Bubnova M G , Aronov D M , Bubnoa Marina , Aronov David

Objective: Objective to study the hypolipidemic efficacy, hepatoprotective activity, and tolerance of the fixed-dose combination of essential phospholipids with methionine (EPL+M) - Eslidine in the combination therapy with A in patients (pts) with cardiovascular diseases (CVD) and type 2 DM who suffer from hyperlipidemia (HL) in order to optimize their treatment in daily clinical practice.Subjects and methods: The trial enrolled 60 pts (mean age 58.1&#17...

ea0032p202 | Cardiovascular Endocrinology & Lipid Metabolism | ECE2013

Dyslipidemia associated with m-TOR inhibitors treatment

Couto Joana , Martins Raquel , Carneiro Filipa , Santos Ana Paula , Torres Isabel

Introduction: Therapeutic approach of patients (pts) with metastatic renal cell carcinoma (mRCC) may include the use of biological agents such as m-TOR inhibitors: temsirolimus (TM) and everolimus (EV). Its use is associated with metabolic dysfunction, especially with everolimus: hyperglycemia (37% TM treated pts vs 72% EV treated pts), hypercholesterolemia (25% TM treated pts vs 81% EV treated pts) and hypertriglyceridemia (30% TM treated pts vs 73% EV treated pts). Discontin...

ea0003s28 | Cell Based Therapies for Treating Neuroendocrine Disease | BES2002

Engineering cells to treat diabetes

Docherty K

The need for new therapeutic options in diabetes has become increasingly apparent. Until recently transplantation of isolated islets has had limited success. The Edmonton Protocol has described how many of the problems can be overcome, but has highlighted the need to develop methods of expanding islets cells in culture to provide sufficient tissue to meet the potentially huge demand for this treatment. We have focused on three approaches: 1. deriving replicating human Beta cel...

ea0094loe1.3 | Section | SFEBES2023

Cell and gene therapy for diabetes

Docherty Kevin

An increased understanding of the DNA sequences and transcription factors (TFs) involved in regulating expression of the insulin gene, and the role that these TFs play in the developing pancreas has opened up new prospects for cell and gene therapy for diabetes. Gene therapy involves injection of an insulin gene construct into muscle, chosen as the most accessible tissue. The major challenges are efficiency of uptake and expression of the exogenous gene, processing of proinsul...

ea0011p782 | Thyroid | ECE2006

Correlation between endogenous thyroxin and A, G, and M immunoglobulins in dysthyreosis

Laszlo A , Pascanu I , Gliga C , Schiopu A , Laszlo M

Introduction: The thyroid is a multifunctional endocrine gland which, by its hormones, affects all the organs, metabolisms and nonspecific defence of the body. The aim of this study is to establish if endogenous thyroxin (FT4) is involved in the nonspecific defence of the organism.Material and methods: 94 patients were included in the study, 47 with hyperthyroidism and 47 with hypothyroidism, 81 women, 13 men aged 7–78. FT4 was...

ea0029p598 | Diabetes | ICEECE2012

Prevalence of diabetes-associated antibodies and impaired insulin response to glucose in first degree relatives of diabetic patients Ebtissam M. Salah*, Hesham El-Hafnawy**, Mona Anwar*, Samar M. E. Salem*, Mai M. Youssef*, Atef Bassyoni** and Marry Aziz**

El Hefnawy M.

Type 1 diabetes is a chronic autoimmune disease with a subclinical prodromal period characterized by the presence of circulating antibodies to various islet cell proteins. Our main objective is to estimate the prevalence of diabetes-associated autoantibodies in a group of 1st degree relatives, compared to healthy control subjects. Also, we tried to assess the insulin secretory capacity in subjects having multiple antibodies using first phase insulin response (FPIR) to intraven...